Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug ...
Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject cohort in a Phase 1 clinical trial of S?1117, a novel engineered Fc-fused ...
GlobalData on MSN5d
Seismic Therapeutic doses first healthy participant cohort in Phase I trial of S-1117US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase ...
Taiho Pharmaceutical Co., Ltd.Araris Biotech AGTaiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris ...
The findings, led by researchers from the Institute of Modern Physics (IMP) of the Chinese Academy of Sciences and their ...
New research highlights a critical link between antibodies produced against Epstein-Barr virus (EBV) and the development of ...
Each time a new wonder drug or superfood pops on the market, I’m skeptical. That didn’t keep me from ordering a certain brand ...
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally administered ...
Maternal stress is a major risk factor for preterm birth (PTB), with recent mouse studies highlighting the role of FKBP51 in stress-induced PTB. This study identifies the 15dPGJ2-mediated inhibition ...
Plans to develop S-1117 for treatment of wide array of IgG autoantibody-driven diseases, such as myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and immune thrombocytopenia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback